English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 26 April 2022, 18:07 HKT/SGT

Source: Legend Capital
Legend Capital Portfolio: Korean Medical AI Company Lunit to List on KOSDAQ in 2Q2022

HONG KONG, Apr 26, 2022 - (ACN Newswire) - Legend Capital's portfolio company Lunit, a Korean Medical AI company, recently announced a preliminary approval from the Korea Exchange for initial public offering (IPO) on the KOSDAQ market, and it plans to submit a registration statement within the second quarter of 2022.

Founded in 2013, Lunit is a company with the world's top-notch AI technology focusing on R&D of medical software to assist tumor diagnosis and treatment. It utilizes advanced AI technology to process medical image data, which helps doctors to make accurate clinical decisions in diagnosis and treatment. Lunit's flagship products are Lunit INSIGHT, an AI image analysis solution for cancer screening, and Lunit SCOPE, an AI biomarker platform for cancer treatment.

According to Korean media reports, Lunit is considered one of the most promising medical AI IPOs in Korea in the first half of 2022. After the listing, Lunit plans to use the secured funding for R&D of AI products and global market development, laying the cornerstone for sustainable growth.

Lunit has partnered with global medical device giants such as GE Healthcare, Philips, and FujiFilm to supply products to about 600 medical sites in more than 40 countries worldwide. In addition, Lunit is also focusing on its biomarker business by signing an exclusive business contract with Guardant Health, a leading global liquid biopsy company.

Brandon Suh, CEO of Lunit, said: "Lunit is the first deep learning-based medical AI company in Korea with a specialized AI research team and medical team, developing AI solutions for cancer diagnosis and treatment. As our AI technologies and products are acknowledged globally, we will strive to continuously grow and pioneer the global medical AI market by going public."

Legend Capital has invested in Lunit 4 times in 2018, 2019, and 2021; it is one of the company's main investors and has long supported its development. Closely following the deep integration of medical and health industry and technology, Legend Capital has built a solid portfolio in medical AI sector in recent years. In addition to Lunit, Legend Capital also invested in a number of other leading medical AI companies, such as Xbiome, an AI-based microbiome drug development company, StoneWise, an AI technology-driven innovative drug R&D platform company, Deepwise Healthcare, an AI medical imaging company, Deep Informatics++, an AI medical pathological diagnosis company, Genome Wisdom, a genomic big data company, and Ayshealth Technology, an AI medical chronic disease management system company.

Topic: Press release summary
Source: Legend Capital

Sectors: BioTech, PE, VC & Alternatives, Artificial Intel [AI]
From the Asia Corporate News Network

Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


Legend Capital Releated News
Aug 15, 2022 16:50 HKT/SGT
Legend Capital Portfolio: China-leading CRO Enterprise R&G Pharmastudies Listed on the ChiNext Market Successfully
Aug 9, 2022 13:06 HKT/SGT
Legend Capital Super Antibiotic Portfolio Company: Scarce Enterprise MicuRx Pharmaceuticals is Listed on the STAR Market Successfully
Aug 8, 2022 13:46 HKT/SGT
New Power to Legend Capital Carbon Neutral Investment Portfolio: Ruicycle Raises Over RMB 300 Million from Series B
July 28, 2022 12:16 HKT/SGT
Led by Legend Capital, The Leading Intelligent Special Robot Company AKA Robotics Completes Series A Financing
July 21, 2022 17:20 HKT/SGT
Legend Capital Portfolio Company: The Global-Leading AI Medical Imaging Company Lunit Goes Public Successfully
More news >>
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575